[1] Hytiroglou P, Theise ND. Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. Virchows Arch, 2018,473:15-22.
[2] Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible Liver Int, 2014,34:85-90.
[3] Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol,2018, 15:274-282.
[4] Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for. J Gastroenterol Hepatol,2018, 33:1009-1015.
[5] Zhu CL, Li WT, Li Y, et al. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J Dig Dis, 2012,13:558-563.
[6] Wang W, Liu R, Su Y, et al. MicroRNA-21-5p mediates TGF-β-regulated fibrogenic activation of spinal fibroblasts and the formation of fibrotic scars after spinal cord injury. Int J Biol Sci, 2018, 14:178-188.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版). 肝脏. 2015,20: 915-932.
[8] Aydln MM, Akcal KC. Liver fibrosis. Turk J Gastroenterol,2018, 29:14-21.
[9] Chen E, Cen Y, Lu D, et al. IL-22 inactivates hepatic stellate cells via downregulation of the TGF-β1/Notch signaling pathway. Mol Med Rep, 2018, 17:5449-5453.
[10] Ye L, Kan F, Yan T, et al. Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice. Sci Rep, 2017, 7:3860.
[11] Hou Z, Quan J. Hepatitis B virus X protein increases microRNA21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway. Mol Med Rep, 2017, 15:3285-3291.
[12] Li W, Zhu C, Wu Y,et al. Increased Pygo2 expression in liver of patients with hepatitis B virus-related fibrosis. Liver Int, 2015, 35: 2522-2529. |
